Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 1
2013 3
2014 2
2017 1
2018 2
2019 2
2020 4
2021 8
2022 6
2023 7
2024 3
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, Laetsch TW. Schultz LM, et al. Among authors: karras na. J Clin Oncol. 2022 Mar 20;40(9):945-955. doi: 10.1200/JCO.20.03585. Epub 2021 Dec 9. J Clin Oncol. 2022. PMID: 34882493 Free PMC article.
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Fabrizio VA, et al. Among authors: karras na. Blood Adv. 2022 Apr 12;6(7):1961-1968. doi: 10.1182/bloodadvances.2021006418. Blood Adv. 2022. PMID: 34788386 Free PMC article.
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.
Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, John S, Rossoff JE, McNerney KO, Fabrizio VA, Talano JA, Moskop A, Curran KJ, Phillips CL, Karras N, Baumeister SHC, Cooper SL, Hermiston M, Satwani P, Qayed M, Raikar SS, MacMillan M, Hall E, Nguyen K, Cassaday RD, Kopmar NE, Kota VK, Mathews J, Shaughnessy P, Schwartz MS, Ladha A, Yaghmour G, Kumaran MV, Bachanova V, Tracy S, Othman T, Luskin MR, Chen EC, Advani AS, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Shah BD, Muffly L, Faramand R. Lust H, et al. Among authors: karras n. Blood Adv. 2025 Jun 10;9(11):2763-2772. doi: 10.1182/bloodadvances.2024014846. Blood Adv. 2025. PMID: 40127395 Free PMC article.
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, Krupski C, Pacenta H, Philips CL, Talano JA, Moskop A, Baumeister SHC, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Kunicki M, Mavroukakis S, Egeler E, Li Y, Mackall CL, Curran KJ, Verneris MR, Laetsch TW, Stefanski H. Schultz LM, et al. Among authors: karras na. J Clin Oncol. 2023 Jan 10;41(2):354-363. doi: 10.1200/JCO.22.01076. Epub 2022 Sep 15. J Clin Oncol. 2023. PMID: 36108252 Free PMC article.
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.
Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano JA, Moskop A, Baumeister S, Verneris MR, Myers GD, Karras NA, Cooper S, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Fabrizio V, Chinnabhandar V, Kunicki M, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Barsan V, et al. Among authors: karras na. EClinicalMedicine. 2023 Oct 26;65:102268. doi: 10.1016/j.eclinm.2023.102268. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37954907 Free PMC article.
Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.
Aldoss I, Shan H, Yang D, Clark MC, Al Malki M, Aribi A, Agrawal V, Sandhu K, Salhotra A, Pourhassan H, Koller P, Ali H, Artz A, Karras N, Pawlowska AB, Murphy L, Palmer J, Stein A, Marcucci G, Pullarkat V, Nakamura R, Forman SJ. Aldoss I, et al. Among authors: karras n. Transplant Cell Ther. 2024 Aug;30(8):788.e1-788.e9. doi: 10.1016/j.jtct.2024.06.013. Epub 2024 Jun 12. Transplant Cell Ther. 2024. PMID: 38876428 Free article.
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.
Naik S, Selukar S, Talleur AC, Deshpande S, Llaurador Caraballo G, Fabrizio VA, Rouce RH, Zeng XL, Vatsayan A, Rossoff J, Pacenta HL, John S, Phillips CL, Talano JA, Moskop A, Verneris MR, Myers GD, Hall E, Karras N, Bonifant CL, Qayed M, Bakinowski E, Keating AK, Baumeister SHC, Tomilson E, Hermiston ML, Satwani P, Krupski C, Chinnabhandar V, Stefanski HE, Egeler E, Curran KJ, Laetsch TW, Mackall CL, Prabhu S, Nguyen KP, Baggott C, Schultz LM, McNerney KO. Naik S, et al. Among authors: karras n. Blood Adv. 2025 Oct 14;9(19):5070-5084. doi: 10.1182/bloodadvances.2025016824. Blood Adv. 2025. PMID: 40690779
Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.
Szabolcs P, Mazor RD, Yackoubov D, Levy S, Stiff P, Rezvani A, Hanna R, Wagner J, Keating A, Lindemans CA, Karras N, McGuirk J, Hamerschlak N, López-Torija I, Sanz G, Valcarcel D, Horwitz ME. Szabolcs P, et al. Among authors: karras n. Transplant Cell Ther. 2023 Aug;29(8):517.e1-517.e12. doi: 10.1016/j.jtct.2023.04.018. Epub 2023 Apr 28. Transplant Cell Ther. 2023. PMID: 37120136 Free article. Clinical Trial.
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM. Moskop A, et al. Among authors: karras na. Blood Adv. 2022 Jul 26;6(14):4251-4255. doi: 10.1182/bloodadvances.2021006393. Blood Adv. 2022. PMID: 35580324 Free PMC article.
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.
Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Fabrizio VA, et al. Among authors: karras na. Blood Adv. 2022 Jan 25;6(2):600-610. doi: 10.1182/bloodadvances.2021005564. Blood Adv. 2022. PMID: 34794180 Free PMC article.
35 results